Ferroptosis has become one of the most closely watched topics in cancer biology. Unlike apoptosis, which quietly dismantles a cell in orderly fragments, ferroptosis is a catastrophic collapse of the cell membrane. It begins when lipid peroxides, generated by iron-catalyzed reactions, accumulate beyond the capacity of cellular antioxidant systems such as glutathione. The membrane disintegrates, mitochondria shrink, and the cell bursts in a process that neighboring immune cells can detect. Because many conventional chemotherapies rely on apoptosis, which tumors routinely learn to evade, researchers have hoped that deliberately triggering ferroptosis could offer a way to kill cancer cells that have outsmarted standard treatments.

The new study began with a clinical question rather than a mechanistic one. Using transcriptomic sequencing of hepatocellular carcinoma specimens collected from patients, alongside data from The Cancer Genome Atlas and the Genotype-Tissue Expression project, the researchers found that CDCA5 is markedly upregulated in liver tumor tissue compared with healthy liver. Higher levels correlated with advanced clinicopathological features and poorer prognosis. Pan-cancer analyses extended the picture across tumor types, linking CDCA5 expression to genomic instability, DNA repair signatures, epigenetic features, immune infiltration patterns, and drug-response profiles, though the authors emphasize that these population-level correlations are primarily descriptive rather than proof of causation.

To test whether CDCA5 actually drives malignant behavior, the team performed gain- and loss-of-function experiments in liver cancer cell lines. When they silenced CDCA5 using short hairpin RNA, the cells lost their ability to proliferate, migrate, and invade. Cell-cycle analysis revealed that depletion of the protein pushed cells into G2/M arrest, halting division at a critical checkpoint. Apoptosis assays and colony-formation tests confirmed the loss of tumorigenic capacity. Conversely, forcing CDCA5 overexpression produced the opposite phenotype, accelerating proliferation and invasion. In mouse xenograft models, tumors lacking CDCA5 grew significantly more slowly than controls, providing in vivo evidence that the protein is not merely a passenger mutation but an active promoter of tumor growth.

The mechanistic twist came when the researchers examined how CDCA5-expressing cells respond to ferroptotic stress. Using C11-BODIPY lipid peroxidation staining, malondialdehyde measurements, reactive oxygen species assays, glutathione quantification, mitochondrial activity tests, and iron measurements, they found that depleting CDCA5 increased every hallmark of ferroptosis: lipid peroxides accumulated, ROS rose, glutathione fell, mitochondria malfunctioned, and intracellular Fe2+ climbed. When the team applied ferroptosis inhibitors, these changes were reversed, confirming that the cell death observed was specifically ferroptotic rather than apoptotic or necrotic.

To trace the signaling route, the researchers turned to proteomic analysis and pharmacological perturbation. They discovered that CDCA5 promotes the expression of PP2Ac, the catalytic subunit of Protein Phosphatase 2A. PP2Ac, in turn, reduces the phosphorylation of p53, the well-known tumor suppressor that normally activates ferroptotic programs. With p53 held in a dephosphorylated, less active state, the transcription of STEAP3, a p53-dependent gene involved in iron metabolism, drops. The result is a tumor cell that is less sensitive to iron-driven membrane collapse. Genetic and pharmacological modulation of PP2Ac and STEAP3, including the use of okadaic acid to inhibit PP2A and pifithrin-alpha to block p53, supported this regulatory axis, and chromatin immunoprecipitation combined with quantitative PCR and dual-luciferase reporter assays confirmed that p53 directly controls STEAP3 transcription.

The findings position CDCA5 as both a biomarker and a functional target. Because elevated CDCA5 correlates with poor prognosis in hepatocellular carcinoma, measuring the protein could help clinicians stratify patients. More intriguingly, the study suggests that pharmacologically disrupting the PP2Ac–p53–STEAP3 axis could restore ferroptotic vulnerability in liver tumors that currently resist this form of cell death. Such an approach would not directly kill cancer cells but would instead prime them for destruction by ferroptosis-inducing agents, potentially offering a combination strategy for hepatocellular carcinoma, a cancer with limited treatment options once it advances beyond surgical resection.

The researchers caution that the pan-cancer correlations between CDCA5 and genomic instability, immune infiltration, and drug response remain primarily correlative and require further validation. The mechanistic work, however, is supported by multiple independent lines of evidence, including rescue experiments, proteomics, and in vivo xenograft models. Because CDCA5 is essential for sister chromatid cohesion and normal cell-cycle progression, any therapeutic strategy targeting it must account for its role in healthy dividing cells, raising the possibility that selective disruption of the ferroptosis-related branch of its function, rather than the protein itself, may prove safer.

For a cancer that remains one of the leading causes of cancer-related death worldwide, the identification of a new regulatory route controlling ferroptosis resistance is a significant step. The study adds CDCA5, better known as Sororin, to a growing list of cell-cycle proteins that moonlight in tumor metabolism, and it highlights the PP2Ac–p53–STEAP3 axis as a potential entry point for restoring ferroptotic sensitivity in hepatocellular carcinoma. As researchers continue to decode how tumors evade iron-driven cell death, this work offers both a mechanistic explanation and a promising therapeutic direction.

Subject of Research: Cell Biology & Cancer

Article Title: CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling

Article References: Wu, D., Zhou, H., Liu, S., Wu, H., Jin, Y., Xing, R., Yang, H., & Wu, G. (2026). CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling. Scientific Reports. https://doi.org/10.1038/s41598-026-74749-0

Image Credits: AI Generated

DOI: 10.1038/s41598-026-74749-0

Keywords: CDCA5, promotes, hepatocellular, carcinoma, progression, suppressing, ferroptosis, PP2Ac, STEAP3, signaling, scientific research